Back to search

Institutional Repository of Vilnius University

UPF3A, BCL-2, R-RAS-2 genų raiškos tyrimas trejopai neigiamo krūties vėžio ligonių kraujo plazmoje /

Abstract

dc:description

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, accounting for 12-18% of cases. The main feature of TNKV is the lack of estrogen (ER), progesterone receptor (PR) and human growth factor 2 receptor (HER2) receptors. Neoadjuvant chemotherapy (NAC) is used to treat patients with TNBC, which is used to reduce the tumor before surgery. However, ~50% of patients develop resistance. Examination of serial liquid biopsy samples during cancer treatment can help to non-invasively understand and monitor the effectiveness of treatment. Blood plasma is most commonly used in liquid biopsy studies. R-RAS-2, BCL-2, and UPF3A act in the STAT3 signaling pathway, and STAT3 is associated with chemotherapy resistance. Detection of these gene expression changes in blood plasma could be used as a non-invasive method to monitor the response to NAC and disease progression during treatment of TNBC patients. Therefore, the aim of this study was to evaluate changes in the expression of UPF3A, BCL-2, R-RAS-2 genes in the blood plasma of TNBC patients during NAC treatment and to determine their suitability for predicting response to treatment and disease progression by RT-qPCR method. A 17% and 7% increase in R-RAS-2 and BCL-2 gene expression was observed after NAC treatment in TNBC patients (P < 0.001; P = 0.026, respectively). A 10% and 11% higher R-RAS-2 gene expression was found in the incomplete response (NA) and residual tumor (RD) groups before NAC (P = 0.013 and P = 0.006, respectively. Also, response to treatment is associated with PD-L1 expression and inherited mutations of the DNA damage repair signaling pathway (DDR). A 12% and 9% higher expression of R-RAS-2 was found in PD-L1-/NA and DDR+ groups after NAC (P = 0.031 and P = 0.027, respectively). Finally, PFS and OS at 40 months were estimated to be 21% and 29% shorter in patients with high UPF3A expression (P = 0.050, HR = 3.47, 95% CI = [10 – 12.0] and P = 0.040, HR = 4.64, 95% CI = [1.0 – 20.5], respectively). These genes could be used as predictive markers for response to NAC and survival prognosis, but more detailed studies are needed.&#8195;.

Degree

thesis:*
Grantor dc:publisher
Institutional Repository of Vilnius University
Year dc:date
2023

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Burauskas, Justas,

Rights

dc:rights
Statement dc:rights
  • info:eu-repo/semantics/openAccess
Language dc:language
lit

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
Vilnius University
Base URL
epublications.vu.lt/oai
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Burauskas, Justas,. UPF3A, BCL-2, R-RAS-2 genų raiškos tyrimas trejopai neigiamo krūties vėžio ligonių kraujo plazmoje /. Institutional Repository of Vilnius University, 2023. https://repository.vu.lt/VU:ELABAETD192843746&prefLang=en_US